source
- London startup Oyster Therapeutics raises $60M to develop oral tau degraders for Alzheimer’sOyster Therapeutics, a London‑based biotech, announced it has closed a $60 million Series A‑2 financing round. The round was led by 4BIO Capital, a life‑science venture capital firm, with addition…
- Deerfield Management teams with AWS to boost AI-driven life-science venturesDeerfield Management announced a collaboration with Amazon Web Services aimed at accelerating AI-native healthcare and life-science companies in its portfolio. The agreement links AWS's generative…